SEMAGLUTIDE AND TIRZEPATIDE IN TYPE 2 DIABETES: PATIENT CHARACTERISTICS AND WEIGHT-RELATED OUTCOMES IN THE REAL-WORLD SETTING

被引：0
|
作者：
Althoff, A. [1 ]
Rasouliyan, L. [1 ]
机构：
[1] OMNY Hlth, Atlanta, GA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD104
引用
收藏
页码：S238 / S239
页数：2
相关论文
共 50 条
  • [1] Real-World Impact of Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-Oral Semaglutide)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Tan, Xi
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Chen, Justin
    King, Aaron A.
    DIABETES, 2023, 72
  • [2] Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting
    Trinh, Huong
    Donovan, Anthony
    McAdam-Marx, Carrie
    DIABETES OBESITY & METABOLISM, 2025,
  • [3] Reality of Real-World Experience with Oral Semaglutide in Type 2 Diabetes
    Singh, Awadhesh Kumar
    Singh, Akriti
    Singh, Ritu
    Swain, Jayshree
    CLINICAL DIABETOLOGY, 2024, 13 (06): : 319 - 322
  • [4] Real-world efficacy data in patients with type 2 diabetes on Semaglutide
    Zitterl, Andreas
    Peric, Slobodan
    Pichler, Maximilian
    Prager, Margarete
    Prager, Rudolf
    Stulnig, Thomas
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 4) : 265 - 265
  • [5] Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
    Kelly, Michael S.
    Scopelliti, Emily M.
    Goodson, Kaylee E.
    Lo, Ching Mann Anne
    Nguyen, Huelena X.
    Simon, Barbara
    DIABETES OBESITY & METABOLISM, 2024, 26 (12): : 5661 - 5668
  • [6] Real-World Impact of Once-Weekly Injectable Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-OW Injectable Semaglutide)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Tan, Xi
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Chen, Justin
    King, Aaron A.
    DIABETES, 2023, 72
  • [7] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [8] Semaglutide in Patients with Type 2 Diabetes: Real-World Data from Spain
    Cardenas-Salas, Jersy J.
    Sierra, Roberto
    Luiza Luca, Bogdana
    Sanchez, Begona
    Modrono, Naiara
    Casado, Carlos
    Sanchez, Nancy M.
    Cruces, Eva
    Vazquez, Clotilde
    DIABETES, 2021, 70
  • [9] Correction to "Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus"
    Kelly, M. S.
    Scopelliti, E. M.
    Goodson, K. E.
    Lo, C. M. A.
    Nguyen, H. X.
    Simon, B.
    DIABETES OBESITY & METABOLISM, 2024,
  • [10] Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice
    Pantanetti, Paola
    Ronconi, Vanessa
    Sguanci, Marco
    Palomares, Sara Morales
    Mancin, Stefano
    Tartaglia, Francesco Carlo
    Cangelosi, Giovanni
    Petrelli, Fabio
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
12345